Growth differentiation factor-15 is a predictive biomarker in primary ventricular fibrillation: The RUTI-STEMI-PVF study

García-García, Cosme; Rueda, Ferran; Lupón, Josep; Oliveras, Teresa; Labata, Carlos; Ferrer, Marc; Cediel, Germán; Diego, Oriol de; Rodriguez-Leor, Oriol; Carrillo, Xavier; Bayés‐Genís, Antoni

doi:10.1177/2048872618797599

Cited by 5 publications

(6 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…19 In patients with STEMI and primary ventricular fibrillation, GDF-15 level was an independent predictor of 30-day mortality. 20 GDF-15 expression was strongly induced in cardiomyocytes by metabolic stresses such as cardiac ischemia, tissue injury or a pressure overload state. 21,22 In a study using a mice model, myocardial ischemia established through coronary artery ligation increased the cardiac expression, but not plasma levels, of GDF-15.…”

Section: Discussionmentioning

confidence: 98%

Combined corrected QT interval and growth differentiation factor‐15 level has synergistic predictive value for long‐term outcome of angiographically confirmed coronary artery disease

et al. 2021

View full text Add to dashboard Cite

Background:The corrected QT interval (QTc) predicts prognosis for the general population and patients with coronary artery disease (CAD). Growth differentiation factor-15 (GDF-15) is a biomarker of myocardial fibrosis and left ventricular (LV) remodelling. The interaction between these two parameters is unknown. Subjects and methods:This study included 487 patients with angiographically confirmed CAD. QTc was calculated using the Bazett formula. Multiple biochemistries and GDF-15 levels were measured. The primary endpoint was total mortality, and the secondary endpoints comprised the combination of total mortality, myocardial infarction and hospitalisation for heart failure and stroke. Results:The mean follow-up period was 1029 ± 343 days (5-1692 days), during which 21 patients died and 47 had secondary endpoints. ROC curve analysis for the optimal cut-off value of primary endpoint is 1.12 ng/mL for GDF-15 (AUC = 0.787,

show abstract

Section: Discussionmentioning

confidence: 98%

Combined corrected QT interval and growth differentiation factor‐15 level has synergistic predictive value for long‐term outcome of angiographically confirmed coronary artery disease

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Thus, circulating levels of GDF-15 have been identified as an inflammatory biomarker with prognostic value in several conditions, particularly in cardiovascular diseases. In the acute setting, increased levels are a robust predictor of organ dysfunction and death from acute myocardial infarction [6, 22, 23] to cardiogenic shock [24]. GDF-15 also serves as biomarker in other critical disease conditions, such as acute pulmonary embolism [25], acute respiratory distress syndrome [26], or sepsis [27].…”

Section: Discussionmentioning

confidence: 99%

“…Moreover, GDF-15 provides information on the severity of disease [5]. In addition, we recently reported that admission levels of GDF-15 could serve as a robust, independent predictor of mortality in primary ventricular fibrillation, due to ST-segment elevation myocardial infarction (STEMI) [6], the most common cause of OHCA.…”

Section: Introductionmentioning

confidence: 99%

Growth differentiation factor 15 and early prognosis after out-of-hospital cardiac arrest

Rueda

Cediel

García-García

et al. 2019

Ann. Intensive Care

View full text Add to dashboard Cite

BackgroundGrowth differentiation factor 15 (GDF-15) is an inflammatory cytokine released in response to tissue injury. It has prognostic value in cardiovascular diseases and other acute and chronic conditions. Here, we explored the value of GDF-15 as an early predictor of neurologic outcome after an out-of-hospital cardiac arrest (OHCA).MethodsProspective registry study of patients in coma after an OHCA, admitted in the intensive cardiac care unit from a single university center. Serum levels of GDF-15 were measured on admission. Neurologic status was evaluated according to the cerebral performance category (CPC) scale. The relationship between GDF-15 levels and poor neurologic outcome at 6 months was analyzed.ResultsAmong 62 patients included, 32 (51.6%) presented poor outcome (CPC 3–5). Patients with CPC 3–5 exhibited significantly higher GDF-15 levels (median, 17.1 [IQR, 11.1–20.4] ng/mL) compared to those with CPC 1–2 (7.6 [IQR, 4.1–13.1] ng/mL; p = 0.004). Multivariable logistic regression analyses showed that age (OR, 1.09; 95% CI 1.01–1.17; p = 0.020), home setting arrest (OR, 8.07; 95% CI 1.61–40.42; p = 0.011), no bystander cardiopulmonary resuscitation (OR, 7.91; 95% CI 1.84–34.01; p = 0.005), and GDF-15 levels (OR, 3.74; 95% CI 1.32–10.60; p = 0.013) were independent predictors of poor outcome. The addition of GDF-15 in a dichotomous manner (≥ 10.8 vs. < 10.8 ng/mL) to the resulting clinical model improved discrimination; it increased the area under the curve from 0.867 to 0.917, and the associated continuous net reclassification improvement was 0.90 (95% CI 0.48–1.44), which allowed reclassification of 37.1% of patients.ConclusionsAfter an OHCA, increased GDF-15 levels were an independent, early predictor of poor neurologic outcome. Furthermore, when added to the most common clinical factors, GDF-15 improved discrimination and allowed patient reclassification.

show abstract

“…Furthermore, it was also suggested to be a prognostic biomarker in the evaluation of short-and long-term outcomes in ST-elevation myocardial infarction (STEMI) patients [148]. Interestingly, in STEMI patients with VF complications, levels of GDF 15 seem to be increased and are also predictive when assessing short-term mortality [149].…”

Section: Other Promising Biomarkersmentioning

confidence: 99%

Classic and Novel Biomarkers as Potential Predictors of Ventricular Arrhythmias and Sudden Cardiac Death

Shomanova

Ohnewein

Schernthaner

et al. 2020

JCM

View full text Add to dashboard Cite

Sudden cardiac death (SCD), most often induced by ventricular arrhythmias, is one of the main reasons for cardiovascular-related mortality. While coronary artery disease remains the leading cause of SCD, other pathologies like cardiomyopathies and, especially in the younger population, genetic disorders, are linked to arrhythmia-related mortality. Despite many efforts to enhance the efficiency of risk-stratification strategies, effective tools for risk assessment are still missing. Biomarkers have a major impact on clinical practice in various cardiac pathologies. While classic biomarkers like brain natriuretic peptide (BNP) and troponins are integrated into daily clinical practice, inflammatory biomarkers may also be helpful for risk assessment. Indeed, several trials investigated their application for the prediction of arrhythmic events indicating promising results. Furthermore, in recent years, active research efforts have brought forward an increasingly large number of “novel and alternative” candidate markers of various pathophysiological origins. Investigations of these promising biological compounds have revealed encouraging results when evaluating the prediction of arrhythmic events. To elucidate this issue, we review current literature dealing with this topic. We highlight the potential of “classic” but also “novel” biomarkers as promising tools for arrhythmia prediction, which in the future might be integrated into clinical practice.

show abstract

Growth differentiation factor-15 is a predictive biomarker in primary ventricular fibrillation: The RUTI-STEMI-PVF study

Abstract: Growth differentiation factor-15 is a robust independent predictor of 30-day mortality in ST-segment elevation myocardial infarction patients with primary ventricular fibrillation.

Cited by 5 publications

References 30 publications

Combined corrected QT interval and growth differentiation factor‐15 level has synergistic predictive value for long‐term outcome of angiographically confirmed coronary artery disease

Combined corrected QT interval and growth differentiation factor‐15 level has synergistic predictive value for long‐term outcome of angiographically confirmed coronary artery disease

Growth differentiation factor 15 and early prognosis after out-of-hospital cardiac arrest

Classic and Novel Biomarkers as Potential Predictors of Ventricular Arrhythmias and Sudden Cardiac Death

Contact Info

Product

Resources

About